1 Assistant Professor of Population Health, Dell Medical School - The University of Texas at Austin, Assistant Professor of Medicine, Department of Medicine, Johns Hopkins School of Medicine (Leung), Osteopathic Medicine Student-II, University of the Incarnate Word School of Osteopathic Medicine (Bernacki), Professor of Population Health, Dell Medical School-The University of Texas at Austin, Professor Emeritus of Medicine, Department of Medicine, Johns Hopkins University School of Medicine (Bernacki).
To evaluate medical and pharmaceutical costs and health outcomes among commercially-insured members treated for Hepatitis C (HCV) infections from a large, academic institution.
Data is derived from the University of Texas System (UT SELECT) medical and pharmacy claims database. This study is a retrospective claims analysis of secondary, de-identified data from 2006-2016.
The number of HCV infected and treated patients decreased from 22.5 per 10,000 members in 2006 to 0.15 per 10,000 members in 2016 (p?
The declining prevalence of acute HCV infections and the introduction of efficacious HCV treatment options for chronic HCV in this commercial population have resulted in significant reductions in HCV-related medical claims and the clinical sequelae of advanced liver diseases. While HCV treatment to achieve sustained viral response (SVR) remains expensive, the prevention of advanced liver disease decreased system-wide medical costs for this insured population.